KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exact Sciences (EXAS) Shares Outstanding (Diluted Average) (2019 - 2025)

Exact Sciences (EXAS) has disclosed Shares Outstanding (Diluted Average) for 10 consecutive years, with $188.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 2.44% to $188.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $188.7 million, a 2.44% increase, with the full-year FY2025 number at $188.7 million, up 2.44% from a year prior.
  • Shares Outstanding (Diluted Average) was $188.7 million for Q4 2025 at Exact Sciences, roughly flat from $188.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $188.9 million in Q2 2025 to a low of $169.4 million in Q1 2021.
  • A 5-year average of $179.9 million and a median of $180.2 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): grew 14.54% in 2021, then decreased 0.14% in 2024.
  • Exact Sciences' Shares Outstanding (Diluted Average) stood at $171.3 million in 2021, then increased by 2.92% to $176.4 million in 2022, then rose by 2.15% to $180.1 million in 2023, then rose by 2.25% to $184.2 million in 2024, then grew by 2.44% to $188.7 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Shares Outstanding (Diluted Average) are $188.7 million (Q4 2025), $188.3 million (Q3 2025), and $188.9 million (Q2 2025).